Literature DB >> 12630033

Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline.

Yasuhiro Fujino1, Yasuyuki Suzuki, Tetsuo Ajiki, Yasuki Tanioka, Yonson Ku, Yoshikazu Kuroda.   

Abstract

BACKGROUND/AIMS: When pancreatic cancer cannot be resected, palliative procedures including gastroenteric bypass and biliary bypass may be selected. However, since predicting survival is difficult, indication of these procedures remains unclear. This study was designed to elucidate the prognostic factors of patients with unresectable pancreatic cancer in order to improve their quality of life.
METHODOLOGY: We treated 187 consecutive patients with unresectable pancreatic cancer at the Kobe University Hospital. Fifteen prognostic variables for survival were analyzed (sex, age, the degree of pain, diet, presence of jaundice, main site of the tumor, tumor size, major vessel invasion, liver metastasis, peritoneal dissemination, distal metastasis and operative procedures) in surgically treated patients (n = 125). All patients were followed until death. Cox's proportional hazard model and logistic regression models were used to determine the factors influencing the survival of patients with unresectable pancreatic cancer.
RESULTS: Cox's proportional hazard model revealed that duodenal invasion (p = 0.001) and liver metastasis (p < 0.0001) significantly influenced the survival of the patients with unresectable pancreatic cancer. In multivariate logistic regression analysis, liver metastasis (p = 0.009) and peritoneal dissemination (p = 0.004) were significant factors on the six-month survival after palliative operation.
CONCLUSIONS: Liver metastasis and peritoneal dissemination were negative predictive factors for the six-month survival of patients with unresectable pancreatic cancer. Palliative bypass surgery is recommended for patients expected to survive long-term (more than six-months).

Entities:  

Mesh:

Year:  2003        PMID: 12630033

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice.

Authors:  Susumu Ishiguro; Kiyoshi Yoshimura; Ryouichi Tsunedomi; Masaaki Oka; Sonshin Takao; Makoto Inui; Atsushi Kawabata; Terrahn Wall; Vassiliki Magafa; Paul Cordopatis; Andreas G Tzakos; Masaaki Tamura
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.

Authors:  Jae Pil Hwang; Ilhan Lim; Kyoung Jin Chang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-30

3.  Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Authors:  Edwina N Scott; Giuseppe Garcea; Helena Doucas; Will P Steward; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

Review 4.  Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature.

Authors:  Marwan Ghosn; Hampig Raphael Kourie; Elie El Rassy; Fady Ghassan Haddad; Colette Hanna; Fadi El Karak; Dolly Nasr
Journal:  World J Gastrointest Oncol       Date:  2016-10-15

5.  Modelling prognostic factors in advanced pancreatic cancer.

Authors:  D D Stocken; A B Hassan; D G Altman; L J Billingham; S R Bramhall; P J Johnson; N Freemantle
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.